Joseph H. Capper
Chief Executive Officer
Mr. Capper joined MIMEDX in January 2023 to lead the Company as Chief Executive Officer and Director. A highly experienced and accomplished healthcare executive, he brings nearly 30 years of experience in MedTech and Life Sciences leadership roles along with a track record of substantial value creation.

Mr. Capper has successfully led several organizations, most recently serving as the CEO of BioTelemetry, guiding the company through a significant turn-around, which culminated with its acquisition by Royal Philips for $2.8 billion. Prior to BioTelemetry, he served as President and CEO of both Home Diagnostics and CCS Medical. Mr. Capper brings with him a wealth of commercial experience, having held several leadership roles earlier in his career during the decade he spent with Bayer AG. Additionally, he was an officer in the U.S. Navy serving with distinction as a naval aviator.

Mr. Capper received his undergraduate degree in Accounting from West Chester University and MBA in International Finance from George Washington University.
Peter M. Carlson
Executive Vice President, Chief Financial Officer

Peter M. Carlson was appointed Chief Financial Officer in March 2020, after joining MiMedx in December 2019 as Executive Vice President of Finance.

Previously, Mr. Carlson served as Chief Operating Officer at Brighthouse Financial, Inc., where he helped establish the $200 billion (assets) U.S. life and annuity insurance company as a separate entity following its August 2017 spin-off from MetLife, Inc. He was the Chief Accounting Officer at MetLife, Inc. for eight years where his global responsibilities included accounting, financial planning, tax, and investment finance. Prior to joining MetLife in 2009, Carlson was the Corporate Controller at Wachovia Corporation.

He currently serves as a director of White Mountains Insurance Company (NYSE: WTM). Mr. Carlson holds a Bachelor of Science from Wake Forest University and is a trustee of the university. He is licensed as a certified public accountant in North Carolina and New York.

John Harper, Ph.D.
Chief Technology Officer and SVP, Research and Product Development
Dr. Harper joined MIMEDX as Chief Technology Officer and Senior Vice President of Research and Product Development in June 2021. Most recently, he served as a Senior Medical Scientist in the Medical Solutions Division of 3M Health Care and Chief Technology Officer for 3M affiliate KCI, where he was responsible for all early-stage research, innovation and technology development and the study of mechanism of action of the company’s negative pressure wound care technology. During his tenure at KCI, Dr. Harper also led the company’s Clinical Development and Regulatory Affairs organization. Prior to KCI, he served as Vice President of Clinical Development and Clinical Sciences at the biotechnology company LifeCell Corporation, the previous Regenerative Medicine division of Acelity and the leader in acellular scaffold technology and makers of AlloDerm, Strattice, and GraftJacket Regenerative and Reconstructive Tissue Matrices.

Dr. Harper has over 40 peer-reviewed publications and book chapters and his principal areas of research interest are extracellular matrix biochemistry, tissue regeneration, and wound healing. He currently serves as a member of the Board of Directors at Kent Imaging, Nanomedic Technologies, and American College of Wound Healing and Tissue Repair.

He received his Ph.D. in Biomedical Sciences from The University of Texas, M.D. Anderson Cancer Center in Houston and completed post-doctoral fellowships in cancer biochemistry and cell biology at Scripps Clinic in La Jolla, California and the National Cancer Institute in Bethesda, Maryland.
William F. “Butch” Hulse
General Counsel and Chief Administrative Officer

Mr. Hulse joined MiMedx in December 2019, and brings to MiMedx more than twenty years’ experience in large law firms and life sciences organizations, with significant legal, risk management, compliance and operational expertise.

Prior to joining the Company, Mr. Hulse was a member of Dykema, a national law firm, since 2017. Prior thereto, he was with Acelity, LP, Inc. (formerly Kinetic Concepts, Inc.) from 2008-2017 in a variety of roles of increasing responsibility. In his last role with Acelity, he served as Chief Compliance Officer and Senior Vice President for Enterprise Risk Management, Quality, and Regulatory. Prior to that, he served as Division General Counsel and Associate General Counsel for litigation matters. Mr. Hulse holds a Bachelor of Arts from Angelo State University and a Juris Doctorate from the Baylor University School of Law.

Kim Moller
SVP, Sales
Ms. Moller joined MIMEDX in August 2020 and brings significant sales leadership experience, clinical knowledge and understanding of the Advanced Wound Care marketplace to her role as Senior Vice President of Sales. With more than 25 years of experience in sales roles with increasing responsibility, Ms. Moller has managed national sales teams and executed on strategic growth initiatives for leading healthcare companies, including 3M and its subsidiaries Acelity and KCI.

Ms. Moller holds a B.S. in Nursing (BSN) from University of Phoenix and an MBA from Colorado Christian University.
Robert B. Stein, M.D., Ph.D.
President, Regenerative Medicine & Biologics Innovation

Dr. Robert B. Stein, M.D., Ph.D. joined MiMedx in August 2020 as Executive Vice President, Research and Development. After completing his Bachelors of Science with honors, earning a double major in both biology and chemistry at Indiana University, Dr. Stein received his M.D. and Ph.D. in Physiology and Pharmacology and completed his internship, residency and Board Certification in Anatomic and Clinical Pathology, all at Duke University. Following residency, Dr. Stein worked at Merck, with contributions to Cozaar, Sustiva, and Gardasil. He was then recruited as the first head of Research and Development for Ligand Pharmaceuticals, with responsibility for building the Research and Development organization and programs targeting various nuclear hormone receptors. This work led to eight pharmaceutical partnerships and six marketed medicines, including two SERMs (Fablyn and Viviant), three novel retinoids (Panretin, Targetin gel and capsules), and Promacta, the small molecule Thrombopoietin mimetic.

After six years at Ligand, he became Executive Vice President, Research and Pre-clinical Development for DuPont-Merck and DuPont pharmaceuticals, leading to the registration of Sustiva and Innohep and the discovery and advancement of blockbuster Eliquis, subsequently registered by Bristol Myers Squibb Company. Following the acquisition of DuPont by Bristol Myers Squibb, Dr. Stein joined Incyte Pharmaceuticals as President, R&D and Chief Scientific Officer, spearheading the transition from genomics to drug discovery and development. Following Incyte, Dr. Stein became President of Roche Palo Alto LLC, where he built Roche’s Translational Medicine capabilities, served on the Global Early Development Committee, Global Biologics Steering Committee, and Joint Roche-Genentech Steering Committee. Dr. Stein then joined Kinemed, a translational medicine company as Chief Executive Officer.

Following Kinemed, Dr. Stein served as President, R&D, for Agenus, an immuno-oncology company, with responsibility for the development of their R&D organization, and the advancement of four checkpoint modulatory antibodies and a personalized neo-epitope-directed cancer vaccine to Phase 1 trials. He also led the generation of a best-in-class TCR discovery and optimization effort. He served as a full time Senior Advisor, R&D, to Agenus and AgenTus from March 2017 to October 2019. During this time, Agenus advanced 13 monoclonal antibodies into the clinic and formed significant partnerships with Incyte, Merck, UCB, and Gilead. The two most advanced Agenus products, AGEN2034 (PD-1 antagonist monoclonal antibody) and AGEN1884 (CTLA-4 antagonist monoclonal antibody) are on track for potential BLA submission in 2020.

Dr. Stein is deeply experienced in the lab, including in the areas of molecular and cellular biology, biochemistry, enzymology, animal pharmacology, virology, drug metabolism, and safety assessment. He also has extensive experience in Translational Medicine and Early Clinical Development. He has led groups of over 1,000 scientists and physicians for over 15 years, supervising work in all the major therapeutic areas. In addition, Dr. Stein serves on the board of directors for a number of private and public company boards, and acts as an advisor to a multiple clients and academic institutions.

Eric Smith
SVP, Marketing & International
Mr. Smith joined MIMEDX in 2021 and currently serves as the Senior Vice President of Marketing & International. Prior to MIMEDX, Mr. Smith was the Chief Commercial Officer at Ascensus Surgical (formerly known as TransEnterix), a global provider of abdominal robotics and augmented reality systems. Prior thereto, he was the Vice President and Global Acute Franchise Leader at Acelity (formerly known as KCI) responsible for all wound care products sold in the hospital setting. He has over 25 years of experience in the health care sector and has held executive level roles at Johnson & Johnson, Boston Scientific and Signet Laboratories.

Mr. Smith holds a B.S. in Business Administration from the University of New Hampshire and an MBA from Babson College.
Kate Surdez
Chief Human Resources Officer

A proven HR executive, Ms. Surdez brings more than 20 years of experience in Human Resources, having led talent acquisition, total rewards, succession and workforce planning, performance coaching, and organizational change management for several successful IPOs and large multinational biotech companies.

She has held a variety of HR roles with increasing responsibility, most recently as the Head of HR for Vaxxinity, a clinical-stage biotech at which she built the HR function from the ground up. Prior thereto, she served as Senior Vice President of HR for Viela Bio, a successful biotech start-up spun out of AstraZeneca that was later acquired by Horizon Therapeutics. Earlier in her career, she provided HR support to multiple functions within the biologics and small molecule teams at MedImmune/AstraZeneca.

Ms. Surdez holds a B.A. in History from the University of North Carolina at Wilmington.

Ricci Whitlow
Chief Operating Officer
Ms. Whitlow joined MIMEDX in January 2023 as Chief Operating Officer. With a demonstrated background in operational leadership, Ms. Whitlow brings to her role more than 30 years of Life Sciences and Pharmaceutical experience.

She has held a variety of senior executive roles, most recently as President, Clinical Supply Services at Catalent Pharma Solutions. Prior to her role at Catalent, Ms. Whitlow’s extensive career has included leadership positions at a number of MedTech and Pharmaceutical companies, including Optinose, LifeCell, Kinetic Concepts, and Johnson & Johnson.

Ms. Whitlow holds a B.S. in Industrial Engineering from Texas A&M University and an MBA from the NYU/LSE/HEC TRIUM program.